A Fibronectin (FN)-Silk 3D Cell Culture Model as a Screening Tool for Repurposed Antifibrotic Drug Candidates for Endometriosis DOI Creative Commons
Sarah Teworte,

Mark C. Behrens,

Mona Widhe

et al.

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 6, 2024

Abstract This study advances sustainable pharmaceutical research for endometriosis by aligning with the UN Sustainable Development Goals on health, gender equality, and responsible consumption in developing vitro 3D cell culture models of endometriotic pathophysiology. Fibrosis is a key aspect endometriosis, yet current to it remain limited, especially 3D. work aims bridge translational gap between fibrosis preclinical testing non-hormonal drug candidates. When grown matrix sustainably produced silk protein functionalized fibronectin-derived adhesion motif (FN-silk), endometrial stromal epithelial cells respond transforming growth factor beta-1 (TGF-β1) physiological manner as probed at mRNA level. For cells, this response TGF-β1 not observed spheroids, while spheroids behave similarly FN-silk networks. Pirfenidone, an antifibrotic approved treatment idiopathic pulmonary fibrosis, reverses TGF-β1-induced upregulation transcripts involved fibroblast-to-myofibroblast transdifferentiation networks, supporting drug’s potential repurposed therapy endometriosis. demonstrates how approach – from project conceptualization material selection can be integrated into women’s health. Table contents paper presents Endometrial cultured networks showed physiological-like fibrotic behavior. Pirfenidone was able reverse , demonstrating model’s suitability screening tool drugs

Language: Английский

A Fibronectin (FN)‐Silk 3D Cell Culture Model as a Screening Tool for Repurposed Antifibrotic Drug Candidates for Endometriosis DOI Open Access
Sarah Teworte,

Mark C. Behrens,

Mona Widhe

et al.

Small, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 19, 2025

Abstract This study advances sustainable pharmaceutical research for endometriosis by developing in vitro 3D cell culture models of endometriotic pathophysiology that allow antifibrotic drug candidates to be tested. Fibrosis is a key aspect endometriosis, yet current it remain limited. work aims bridge the translational gap between fibrosis and preclinical testing non‐hormonal candidates. When grown matrix sustainably produced silk protein functionalized with fibronectin‐derived adhesion motif (FN‐silk), endometrial stromal epithelial cells respond transforming growth factor beta‐1 (TGF‐β1) physiological manner as probed at messenger RNA (mRNA) level. For cells, this response TGF‐β1 not observed spheroids, while spheroids behave similarly FN‐silk networks. Pirfenidone, an approved treatment idiopathic pulmonary fibrosis, reverses TGF‐β1‐induced upregulation mRNA transcripts involved fibroblast‐to‐myofibroblast transdifferentiation networks, supporting pirfenidone's potential repurposed therapy. Overall, cultured networks—which are composed produced, fully defined protein—recapitulate fibrotic cellular behavior high fidelity enable testing.

Language: Английский

Citations

0
Development of regenerative therapies targeting fibrotic endometrium in intrauterine adhesion or thin endometrium to restore uterine function DOI
Guangfeng Zhao, Jianwu Dai, Yali Hu

et al.

Science China Life Sciences, Journal Year: 2025, Volume and Issue: unknown

Published: April 11, 2025

Language: Английский

Citations

0
Novel therapeutic strategies for Asherman's syndrome: Endometrial regeneration using menstrual blood-derived stem cells DOI

Sena Awano-Kim,

Satoshi Hosoya, Ryo Yokomizo

et al.

Regenerative Therapy, Journal Year: 2025, Volume and Issue: 29, P. 328 - 340

Published: April 7, 2025

Language: Английский

Citations

0
A Fibronectin (FN)-Silk 3D Cell Culture Model as a Screening Tool for Repurposed Antifibrotic Drug Candidates for Endometriosis DOI Creative Commons
Sarah Teworte,

Mark C. Behrens,

Mona Widhe

et al.

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 6, 2024

Abstract This study advances sustainable pharmaceutical research for endometriosis by aligning with the UN Sustainable Development Goals on health, gender equality, and responsible consumption in developing vitro 3D cell culture models of endometriotic pathophysiology. Fibrosis is a key aspect endometriosis, yet current to it remain limited, especially 3D. work aims bridge translational gap between fibrosis preclinical testing non-hormonal drug candidates. When grown matrix sustainably produced silk protein functionalized fibronectin-derived adhesion motif (FN-silk), endometrial stromal epithelial cells respond transforming growth factor beta-1 (TGF-β1) physiological manner as probed at mRNA level. For cells, this response TGF-β1 not observed spheroids, while spheroids behave similarly FN-silk networks. Pirfenidone, an antifibrotic approved treatment idiopathic pulmonary fibrosis, reverses TGF-β1-induced upregulation transcripts involved fibroblast-to-myofibroblast transdifferentiation networks, supporting drug’s potential repurposed therapy endometriosis. demonstrates how approach – from project conceptualization material selection can be integrated into women’s health. Table contents paper presents Endometrial cultured networks showed physiological-like fibrotic behavior. Pirfenidone was able reverse , demonstrating model’s suitability screening tool drugs

Language: Английский

Citations

0